Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Jun 1, 2009
SAN DIEGO, June 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial has been accepted for a poster presentation at the American Diabetes A...
May 13, 2009
SAN DIEGO, May 13, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 34th Annual Deutsche Bank Health Care Conference on May 19, 2009 at 10:10 a.m. Eastern Time (7:10 a.m. Pacific Time) at the InterContinental Boston Hotel in Boston...
May 11, 2009
SAN DIEGO, May 11, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the first quarter ended March 31, 2009. Arena reported a net loss allocable to common stockholders in the first quarter of 2009 of $50.6 million, or $0.68 per share, compared to a net loss ...
May 5, 2009
SAN DIEGO, May 5, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report first quarter 2009 financial results after the NASDAQ Global Market closes on Monday, May 11, 2009. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoff...
Mar 30, 2009
SAN DIEGO, March 30, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today positive top-line results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight ...
Mar 29, 2009
SAN DIEGO, March 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will hold a conference call and webcast on Monday, March 30, 2009 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss top-line results from BLOOM (Behavioral modification and Lorcaserin for Overweight a...
Mar 23, 2009
SAN DIEGO, March 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today it has obtained an equity financing commitment of up to $50 million from Azimuth Opportunity Ltd. During the 18-month term of the equity financing commitment, Arena may sell newly issued registered shares of its com...
Mar 12, 2009
SAN DIEGO, March 12, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the fourth quarter and full year ended December 31, 2008. Arena reported a net loss allocable to common stockholders in the fourth quarter of 2008 of $62.5 million, or $0.84 per share, an...
Mar 5, 2009
SAN DIEGO, March 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report fourth quarter and full year 2008 financial results after the NASDAQ Global Market closes on Thursday, March 12, 2009. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, an...
Feb 18, 2009
SAN DIEGO, Feb 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of a Phase 2 clinical trial of an orally administered niacin receptor agonist drug candidate being developed by Merck & Co., Inc., under its collaboration with Arena to treat atherosclerosis. Agonists o...
Feb 4, 2009
SAN DIEGO, Feb 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BIO CEO & Investor Conference on February 10, 2009 at 1:45 p.m. Eastern Time (10:45 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. Jack Lief, Arena's ...
Jan 8, 2009
SAN DIEGO, Jan 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 27th Annual J.P. Morgan Healthcare Conference on January 14, 2009 at 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time) at the Westin St. Francis Hotel in San Francisco. J...
Dec 15, 2008
SAN DIEGO, Dec 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Ortho-McNeil) initiated under their partnership a first-in-human Phase 1 clinical trial of APD597, a novel oral drug candidate discovered by Arena that targets the gluc...
Dec 9, 2008
SAN DIEGO, Dec 09, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced preliminary data from a Phase 2b clinical trial of APD125 measuring subjective endpoints in patients with primary insomnia. The initial data analysis indicates that APD125 did not meet the trial's primary or secondary...
Dec 8, 2008
SAN DIEGO, Dec 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host a Research and Development Day on Monday, December 15, 2008, beginning at approximately 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time). Speakers, including Jack Lief, President and Chief Execut...
= add release to Briefcase